EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2

Nadine M Tung iD, Mark E Robson iD, Tianyu Li, Rita Nanda iD, Payal D Shah iD, Katia Khoury iD, Gretchen Kimmick iD, Cesar Santa-Maria iD, Adam Brufsky iD, Michelle DeMeo, Joao Pedro Vieira, Lisa A Carey iD und 7 weitere

Journal of Clinical Oncology · 10.03.2026 · 44 (8) · 653-661

DOI: 10.1200/jco-25-02075 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.03.2026. Verfasst von Nadine M Tung und 18 weiteren Autor:innen. Beteiligte Einrichtung: Beth Israel Deaconess Medical Center, Boston, MA. Hauptthemen laut MEDLINE: Phthalazines, Germ-Line Mutation, Piperazines, Fanconi Anemia Complementation Group N Protein. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Translational Breast Cancer Research Consortium 048 was a proof-of-principle trial demonstrating responses to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in patients (pts) with metastatic breast cancer (MBC) with germline (g) PALB2 or somatic (s) BRCA mutations (s BRCA m). Here we report results from the expansion cohorts in a larger sample of pts with g PALB2 m or s BRCA m. METHODS Eligible pts had MBC of any subtype with measurable disease and a g PALB2 m or s BRCA m. Pts received olaparib 300 mg twice a day until progression. The primary end point was overall response rate. Secondary end points include clinical benefit rate (CBR) at 18 weeks, progression-free survival (PFS), duration of response (DOR), and whether among s BRCA m carriers the mutant allele frequency (MAF) is significantly higher in responders than in nonresponders. RESULTS Fifty-four pts with g PALB2 m (N = 24) or s BRCA m (N = 30) were enrolled. Forty-two (78%) had estrogen receptor–positive human epidermal growth factor receptor 2–negative (HER2–) MBC, seven (13%) had triple-negative breast cancer, and five (9%) had HER2+ disease. Among pts with a g PALB2 m, the overall response rate (ORR) was 75% (80% CI, 60.2 to 86.3), CBR was 83.3% (90% CI, 65.8 to 94.1), the median PFS was 9.4 months (90% CI, 8.3 to 13.1), and the median DOR was 7.0 months (90% CI, 5.6 to 10.4). Among pts with s BRCA m (15 s BRCA1 and 15 s BRCA2 ), the ORR was 36.7% (80% CI, 24.7 to 50), CBR was 53.3% (90% CI, 37 to 69.1), the median PFS was 5.5 months (90% CI, 2.8 to 8.3), and the median DOR was 11.2 months (90% CI, 4.4 to not reached). One additional pt had an unconfirmed partial response. Although clinically meaningful, the ORR in pts with s BRCA m did not achieve the prespecified target. Among s BRCA m carriers, the mean MAF did not differ significantly between responders (46%) and nonresponders (39%; P = .7). CONCLUSION Olaparib is active in pts with MBC with g PALB2 m and s BRCA m, significantly expanding the population of pts with breast cancer likely to benefit from PARP inhibitors beyond g BRCA1/2 m carriers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesGerm-Line MutationPiperazinesFanconi Anemia Complementation Group N ProteinBreast NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsBRCA2 ProteinBRCA1 ProteinHumansFemaleMiddle AgedAgedAdultProgression-Free Survival

Substanzen

PhthalazinesolaparibPiperazinesFanconi Anemia Complementation Group N ProteinPALB2 protein, humanBRCA2 protein, humanPoly(ADP-ribose) Polymerase InhibitorsBRCA1 protein, humanBRCA2 ProteinBRCA1 Protein

Autor:innen und Institutionen

  • Beth Israel Deaconess Medical Center, Boston, MA.
  • Harvard Medical School, Boston, MA.
  • Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Dana-Farber Cancer Institute, Boston, MA.
  • The University of Chicago, Chicago, IL.
  • Basser Center for BRCA, University of Pennsylvania, Philadelphia, PA.

ORCID-Profile: Nadine M Tung, Mark E Robson, Rita Nanda, Payal D Shah, Katia Khoury, Gretchen Kimmick, Cesar Santa-Maria, Adam Brufsky, Lisa A Carey, Gerburg Wulf, Susan Domchek, Ian E Krop, Antonio C Wolff, Eric P Winer, Judy E Garber

Zitieren

APA

Tung, N. M., Robson, M. E., Li, T., Nanda, R., Shah, P. D., Khoury, K., Kimmick, G., Santa-Maria, C., Brufsky, A., DeMeo, M., Vieira, J. P., Carey, L. A., Wulf, G., Domchek, S., Krop, I. E., Wolff, A. C., Winer, E. P., Garber, J. E., & Translational Breast Cancer Research Consortium (TBCRC) (2026). TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2. Journal of Clinical Oncology, 44(8), 653-661. https://doi.org/10.1200/jco-25-02075

Vancouver

Tung NM, Robson ME, Li T, Nanda R, Shah PD, Khoury K, et al. TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2. Journal of Clinical Oncology. 2026;44(8):653-661. doi:10.1200/jco-25-02075

BibTeX
@article{Tung2026,
  author = {Tung, Nadine M and Robson, Mark E and Li, Tianyu and Nanda, Rita and Shah, Payal D and Khoury, Katia and Kimmick, Gretchen and Santa-Maria, Cesar and Brufsky, Adam and DeMeo, Michelle and Vieira, Joao Pedro and Carey, Lisa A and Wulf, Gerburg and Domchek, Susan and Krop, Ian E and Wolff, Antonio C and Winer, Eric P and Garber, Judy E and Translational Breast Cancer Research Consortium (TBCRC), Translational Breast Cancer Research Consortium (TBCRC)},
  title = {TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {8},
  pages = {653--661},
  doi = {10.1200/jco-25-02075}
}
Kostenlos starten →